|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
These results are consistent with the idea that the <i>UGT2B15</i> D85Y enzyme variant reduces the risk of prostate cancer by efficiently metabolizing dihydrotestosterone (DHT), which is associated with prostate cancer progression.
|
28881775 |
2017 |
|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our findings suggest that the D85Y polymorphism of UGT2B15 and CNVs in UGT2B28 and UGT2B17 genes is not associated with prostate cancer risk in Iranian patients.
|
28882566 |
2017 |
|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study replicates the results that show an association of UGT215(D85Y) with an increased prostate cancer risk.
|
23098242 |
2013 |
|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We have previously shown that a functional polymorphism of the UGT2B15 gene (rs1902023) was associated with increased risk of prostate cancer (PC).
|
24267955 |
2013 |
|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Polymorphism D85Y in gene UGT2B15 correlates with differentiation of PCa.
|
15065092 |
2004 |
|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
These results suggest that the UGT2B15 enzyme may have a role in the metabolism of dihydrotestosterone in prostate tissue and UGT2B15 Asp85Tyr polymorphism is associated with prostate cancer risk.
|
15126881 |
2004 |
|
rs1902023
|
|
|
0.070 |
GeneticVariation |
BEFREE |
An allele-specific polymerase chain reaction method for the determination of the D85Y polymorphism in the human UDP-glucuronosyltransferase 2B15 gene in a case-control study of prostate cancer.
|
11129427 |
2000 |
|
rs13112099
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for race, age and BMI, we found that six UGT2B15 SNPs (rs4148269, rs3100, rs9994887, rs13112099, rs7686914 and rs7696472) were associated with an increased risk of PC in log-additive models (p < 0.05).
|
24267955 |
2013 |
|
rs3100
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A SNP cis-acting on UGT2B17 and UGT2B15 expression (rs17147338) was also associated with increased risk of prostate cancer (OR = 1.65, 95% CI = 1.00-2.70); while a stronger association among men with high Gleason sum was observed for SNPs rs4148269 and rs3100.
|
24267955 |
2013 |
|
rs4148269
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A SNP cis-acting on UGT2B17 and UGT2B15 expression (rs17147338) was also associated with increased risk of prostate cancer (OR = 1.65, 95% CI = 1.00-2.70); while a stronger association among men with high Gleason sum was observed for SNPs rs4148269 and rs3100.
|
24267955 |
2013 |
|
rs7686914
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for race, age and BMI, we found that six UGT2B15 SNPs (rs4148269, rs3100, rs9994887, rs13112099, rs7686914 and rs7696472) were associated with an increased risk of PC in log-additive models (p < 0.05).
|
24267955 |
2013 |
|
rs7696472
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After adjusting for race, age and BMI, we found that six UGT2B15 SNPs (rs4148269, rs3100, rs9994887, rs13112099, rs7686914 and rs7696472) were associated with an increased risk of PC in log-additive models (p < 0.05).
|
24267955 |
2013 |